FDA weighs changes to policy on advisor conflicts

FDA may loosen its conflicts-of-interest rules governing scientists who serve on its advisory committees, Commissioner Margaret Hamburg said, in an attempt to ensure that it gets enough expert feedback on potential drug approvals and safety moves. Report

Suggested Articles

A suspected cancer-causing impurity that has been found in some blood pressure medicines has now shown up in Zantac and some OTC antacids.

Roche is steamrolling with Ocrevus, and to maintain that lead, its touting long-term data that show the earlier it’s given, the better patients do.

New data shows a significant reduction in relapse rates in patients taking Novartis' repurposed cancer drug ofatumumab.